MPG.eBooks - Description: Elosulfase alfa (Vimizim)

Cover Image

Read Now

Elosulfase alfa (Vimizim)

The objective of this review was to evaluate the beneficial and harmful effects of elosulfase alfa (ESA) 2mg/kg IV once weekly as long-term enzyme replacement therapy in patients with mucopolysaccharidosis IVA; Morquio A syndrome (MPS IVA)

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2015, 2015
Series:	Common drug review
Subjects:	Chondroitinsulfatases / Therapeutic Use Mucopolysaccharidosis Iv / Drug Therapy Treatment Outcome
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK362610
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this review was to evaluate the beneficial and harmful effects of elosulfase alfa (ESA) 2mg/kg IV once weekly as long-term enzyme replacement therapy in patients with mucopolysaccharidosis IVA; Morquio A syndrome (MPS IVA)
Physical Description:	1 PDF file illustration